Skip to main content

Table 4 ICERs of scenario analyses from the Chinese healthcare perspective (CNY per QALY gained)

From: Methodology and results of cost-effectiveness of LDL-C lowering with evolocumab in patients with acute myocardial infarction in China

 

PEACE

BERSON

SuValue®

LDL-C ≥ 100 mg/dl

SuValue®

LDL-C ≥ 70 mg/dl

Evo 140mgQ2W

Evo 420mgQM

Evo 140mgQ2W

Evo 420mgQM

Evo 140mgQ2W

Evo 420mgQM

Evo 140mgQ2W

Evo 420mgQM

Time horizon

        

5 years

560431.63

862489.78

501332.97

893539.69

195951.91

242966.70

322809.94

557316.71

10 years

284569.36

440560.92

242330.14

439597.72

94332.72

194182.08

160883.45

285355.56

15 years

191287.82

296835.37

154973.97

284122.89

62166.54

131380.50

107590.05

193482.78

20 years

152155.45

236588.60

114428.44

211855.12

47781.40

103208.66

83668.90

152268.70

30 years

134240.70

209956.59

86535.32

163514.29

37302.63

84166.61

67030.66

124934.42

35 years

133083.42

208719.66

83376.17

158919.09

NA

NA

NA

NA

Starting age

        

65-year

121365.52

172717.45

73383.57

138037.76

NA

NA

NA

NA

70-year

103267.71

150351.27

56517.58

108060.03

39605.72

87392.58

70034.35

129059.14

75-year

84946.74

126891.51

42483.76

83985.21

30553.67

68195.31

53678.13

99970.03

Discount rate

        

3%

123519.88

192790.91

83849.77

157503.59

36035.97

80462.88

64207.24

119040.93

6%

145241.79

226352.26

100806.54

188192.28

43473.21

95365.52

76801.17

140974.87

Annual Cost of Stains (CNY)a

        

118.86

131102.46

212813.67

93705.52

176282.05

38710.07

88018.74

70251.67

131192.08

5470.28

134976.64

216654.87

95526.50

178110.59

43004.30

92312.97

74550.88

135491.29

Costs of CV-related deathb

        

Death due to stroke 1

116570.06

193592.63

73068.07

155525.57

16745.35

66054.01

48025.65

108966.06

Death due to stroke 2

130382.94

207405.52

87351.56

169888.68

32541.32

81849.98

63999.21

124939.62

Death due to MI 1

118319.42

195341.99

68158.82

150384.52

6528.07

55836.73

39090.98

100031.39

Death due to MI 2

92301.26

169323.84

35964.22

117891.62

Dominance

17416.88

1113.88

62054.29

Utilityc

        

Higher utility

156999.82

244782.59

103011.41

193226.79

45005.11

99255.17

80019.62

147327.16

Lower utility

126564.51

197330.08

89484.04

166987.79

38284.51

84433.42

67616.20

124490.76

UK- utility

146062.51

227729.93

100800.52

187476.68

42461.83

93646.16

74998.51

138082.62

Hospital classification

        

County hospitals

154811.12

231833.69

113682.98

196641.29

67932.09

117240.76

98423.88

159364.30

County-level municipal hospitals

150510.37

227532.95

108608.40

191463.97

60612.92

109921.59

91418.36

152358.77

Prefecture-level municipal hospitals

136460.69

213483.27

93365.00

175916.39

38748.53

88057.20

70387.91

131328.32

Provincial hospitals

134431.86

211454.44

90173.78

172658.18

34080.28

83388.94

65984.28

126924.69

Hospitals directly under the Health Commission

129164.77

206187.35

84385.48

166754.78

25788.08

75096.74

58021.98

118962.39

  1. CNY, Chinese Yuan; Dominance, ICERs, incremental cost-effectiveness ratio; Lower cost, higher utility; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; NA, not applicable
  2. italic text: ICERs below CNY 85698 (US$12741); bold text: ICERs above CNY 257094 (US$38224).
  3. a: the maximum and minimum annual cost of statins, more detailed parameters are shown in Supplementary Tables S4
  4. b: CV-related mortality costs used in other CEA studies and beyond the scope of sensitivity analysis, more detailed parameters are shown in Supplementary Tables S5
  5. c: Utility used in other CEA studies and beyond the scope of sensitivity analysis, more detailed parameters are shown in Supplementary Tables S6
Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us